✦ LIBER ✦

Personality Diagnostic Questionnaire 4+ is not Useful as a Screener in Clinical Practice

✍ Scribed by Rob J. M. de Reus; Julia F. van den Berg; Paul M. G. Emmelkamp

Book ID: 112069425
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 179 KB
Volume: 20
Category: Article
ISSN: 1063-3995
DOI: 10.1002/cpp.766

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

UP-02.090 Expression of CD147 Protein Is

UP-02.090 Expression of CD147 Protein Is Not Useful as Presurgical Diagnostic Factor in Human Prostate Cancer

✍ M. Schmudermaier; A. Lunacek; M. Huber; A. Nader; E. Plas 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 73 KB

A survey of ATRIPLA use in clinical prac

A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

✍ Mocroft, A.; Reiss, P.; Rakhmanova, A.; Banhegyi, D.; Phillips, A. N.; De Wit, S 📂 Article 📅 2014 🏛 Springer-Verlag 🌐 English ⚖ 311 KB

The clinical and histopathologic spectru

The clinical and histopathologic spectrum of “dermal hypersensitivity reactions,” a nonspecific histologic diagnosis that is not very useful in clinical practice, and the concept of a “dermal hypersensitivity reaction pattern”

✍ Maxwell A. Fung 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 257 KB

Thiazolidinedione use is not associated

Thiazolidinedione use is not associated with worse cardiovascular outcomes: A study in 28,332 high risk patients with diabetes in routine clinical practice

✍ Roussel, Ronan; Hadjadj, Samy; Pasquet, Blandine; Wilson, Peter W.F.; Smith, Sid 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 226 KB

RISK-ADAPTED SCREENING IN BLADDER CANCER

RISK-ADAPTED SCREENING IN BLADDER CANCER AS A NEW STRATEGY IN BLADDER CANCER IS FEASIBLE USING A COMPUTER-BASED QUESTIONNAIRE, RISIKOCHECK V4.0, EVALUATED IN AN INTERNATIONAL MULTICENTRE TRIAL

✍ G. Luedecke; P. Tuerker; B. Guenluesoy; A. Yildirim; G. Aslan; A. Mungan; S. Bal 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 72 KB

The Disease Activity Score is not suitab

The Disease Activity Score is not suitable as the sole criterion for initiation and evaluation of anti–tumor necrosis factor therapy in the clinic: Discordance between assessment measures and limitations in questionnaire use for regulatory purposes

✍ Frederick Wolfe; Kaleb Michaud; Theodore Pincus; Daniel Furst; Edward Keystone 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB 👁 2 views

## Abstract ## Objective The Disease Activity Score (DAS) is widely used in clinical trials. A DAS of 5.1 defines the level of severe rheumatoid arthritis (RA) and is the criterion for the initiation of anti–tumor necrosis factor therapy in the UK and The Netherlands. In North America, similar rul